Cure SMA Awards $140,000 Grant to Arthur Burghes, PhD, The Ohio State University

Leave a Comment / Front Page News, Our Impact, Research /

Cure SMA has awarded a $140,000 research grant to Arthur Burghes, PhD, at The Ohio State University, for his project, “Identification of SMA modifiers and deletion/duplication junctions in the SMA region.” All individuals with SMA lack the SMN1 gene, but have one or more copies of SMN2, the SMA “backup gene.” In general, those with […]

Cure SMA Awards $140,000 Grant to Arthur Burghes, PhD, The Ohio State University Read More »

Cure SMA Releases Care Series Booklet on Insurance

Leave a Comment / Front Page News, Support & Care /

Cure SMA is excited to announce the launch of our newest care series booklet, Choice and Connection to Care: A Health Insurance Roadmap for People Living with Spinal Muscular Atrophy (SMA) and Their Caregivers. You can download a copy of this booklet now from our website, or send an email to [email protected] to request a

Cure SMA Releases Care Series Booklet on Insurance Read More »

SMA is Submitted to the Federal Newborn Recommended Uniform Screening Panel (RUSP)

Leave a Comment / Advocacy, Front Page News, Our Impact /

Cure SMA and the SMA Newborn Screening Coalition are excited to announce we have completed the submission of SMA to the Recommended Uniform Screening Panel (RUSP). Administered by the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC), part of the Department of Health and Human Services, the RUSP is a list of

SMA is Submitted to the Federal Newborn Recommended Uniform Screening Panel (RUSP) Read More »

Announcing an Evening of Wonder at Magic Kingdom Park

Leave a Comment / Conference, Front Page News /

Just added to this year’s conference schedule: Saturday night at Magic Kingdom Park! We are excited to announce that each conference attendee will get to participate in this classic Disney World evening, sponsored by Biogen. All registered participants will receive complimentary Saturday Disney Entrance to Magic Kingdom Park, and the opportunity to watch the Happily

Announcing an Evening of Wonder at Magic Kingdom Park Read More »

Cure SMA to Host Webinar with the FDA and Patient Advocates

Leave a Comment / Advocacy, Community Awareness, Front Page News /

Cure SMA is pleased to announce a new webinar on interactions between the FDA and the SMA community. The webinar will be held on March 8, 2017, at 1:00pm EST (10:00am PST/ 11:00am MST/ 12:00pm CST).  The goal is to provide both a broad overview of how our community can continue to productively engage with

Cure SMA to Host Webinar with the FDA and Patient Advocates Read More »

Registration Opens for the SMA Patient-Focused Drug Development Meeting with the FDA

Leave a Comment / Advocacy, Front Page News, Our Impact /

Registration is now open for the SMA Patient-Focused Drug Development (PFDD) meeting with the FDA. The PFDD meeting will be held at the College Park Marriott, near Washinton DC, on Tuesday, April 18.  There are two primary ways to participate in this meeting:  Attend in person. Registration for in-person attendance is free, but seating is

Registration Opens for the SMA Patient-Focused Drug Development Meeting with the FDA Read More »

Spinraza Access Update Webinar

Leave a Comment / Community Awareness, Front Page News /

On Tuesday, February 14, at 1:00pm EST (10:00am PST/11:00am MST/12:00pm CST), Cure SMA hosted a webinar updating the community on the status of Spinraza access. Among the topics covered were adminstration sites, insurance coverage, and community resources and support programs.  We were happy to host an open, candid, and informal discussion of where our community

Spinraza Access Update Webinar Read More »

Cure SMA Launches Community Survey to Address Urgent and Important Issues in SMA Treatment

Leave a Comment / Community Awareness, Front Page News /

For the past several years, we’ve been working to collect data and information on our community’s experiences, goals, hopes and challenges. We know that the voice of our community is powerful. By sharing our stories, we can communicate our priorities to the FDA and regulators, provide insight into daily life with SMA and the ongoing

Cure SMA Launches Community Survey to Address Urgent and Important Issues in SMA Treatment Read More »

Biogen Presents New ENDEAR Data Showing SPINRAZA (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation

Leave a Comment / Clinical Trials, Front Page News, Research /

Biogen presented new data from the Phase 3 ENDEAR study of SPINRAZA™ (nusinersen), which demonstrated a statistically significant reduction in the risk of death or permanent ventilation in SPINRAZA-treated infants with spinal muscular atrophy (SMA), compared to untreated infants. The data was presented at the British Pediatric Neurology Association (BPNA) annual conference in Cambridge, UK,

Biogen Presents New ENDEAR Data Showing SPINRAZA (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation Read More »

Updated SMA Drug Pipeline Released as First Commercial Patient Receives Spinraza

Leave a Comment / Advocacy, Community Awareness, Front Page News /

With the news today that the first-ever patient has received the first commercial Spinraza dose, we are releasing an updated version of our SMA drug pipeline. This new version reflects the approval of Spinraza, as well as the true start of a key stage to ensure that more and more patients are able to gain

Updated SMA Drug Pipeline Released as First Commercial Patient Receives Spinraza Read More »

Scroll to Top